LBRX Latest Press Releases

-- October 15, 2026 --

LB Pharmaceuticals to Participate in Upcoming Investor Events Globe Newswire 4:05 PM

-- October 10, 2026 --

LB Pharmaceuticals Presents New Preclinical Data Supporting LB-102's Bimodal Mechanism of Action and Highlights Ongoing Late-Stage Clinical Development Programs at the 39th ECNP Congress Globe Newswire 8:00 AM

-- October 9, 2026 --

LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:42 PM

-- October 6, 2026 --

LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB-102 with a Focus on Schizophrenia Treatment Globe Newswire 8:00 AM

-- September 15, 2026 --

LB Pharmaceuticals Appoints Susan G. Kozauer, M.D. as Chief Medical Officer Globe Newswire 8:00 AM

-- September 3, 2026 --

LB Pharmaceuticals to Participate in Upcoming September Investor Events Globe Newswire 4:05 PM

LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer Globe Newswire 8:00 AM

-- August 11, 2026 --

LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update Globe Newswire 8:00 AM

-- July 29, 2026 --

LB Pharmaceuticals Announces $150 Million Private Placement Globe Newswire 8:00 AM

-- July 22, 2026 --

LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia Globe Newswire 8:00 AM

-- July 10, 2026 --

LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:38 PM

-- June 30, 2026 --

LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations Globe Newswire 8:00 AM

-- May 28, 2026 --

LB Pharmaceuticals to Participate in Upcoming June Investor Events Globe Newswire 4:05 PM

Market Data Delayed 15 Minutes